Fidelity Investments’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Fidelity Investments’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-966,226	Closed	-$3.08M	–	5734
2022 Q1	$3.08M	Sell	966,226 -1,000	-0.1%	-$2.88K	﹤0.01%	2490
2021 Q4	$2.78M	Buy	967,226 +1,000	+0.1%	+$3.73K	﹤0.01%	2492
2021 Q3	$3.84M	Hold	966,226	–	–	﹤0.01%	2428
2021 Q2	$5.76M	Hold	966,226	–	–	﹤0.01%	2290
2021 Q1	$11.7M	Hold	966,226	–	–	﹤0.01%	1981
2020 Q4	$14.1M	Hold	966,226	–	–	﹤0.01%	1849
2020 Q3	$11.1M	Buy	+966,226	New	+$12.4M	﹤0.01%	1802

Fidelity Investments's CMPI Position: Q2 2022 in Review

Fidelity Investments sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 966,226 shares — an estimated $3.08M sold.

Fidelity Investments first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $14.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Fidelity Investments reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Fidelity Investments sold 966,226 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $3.08M.
Fidelity Investments first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Fidelity Investments's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $14.1M in Q4 2020.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Fidelity Investments's 13F filing for Q2 2022, filed 12 Aug 2022.